APIFARMA - Portuguese Pharmaceutical Industry Association

apifarma.pt

The Portuguese Association of the Pharmaceutical Industry – APIFARMA - was established in 1975, and succeeds the National Guild of the Manufacturers of Medicinal Products, in order to contribute to solving the problems of the sector, for the socioeconomic development of the country, for the improvement of health in Portugal and patient access to new therapies. Currently, APIFARMA represents more than 120 companies responsible for the Production and Marketing of Medicinal Products for Human and Veterinary Use, Vaccines, and In Vitro Diagnostics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CANNABIS INDUSTRY GIANT WAYOFLEAF.COM EXPANDS HEALTH-SPECIFIC CONTENT, INTRODUCES MEDICAL REVIEW TEAM

Prnewswire | September 30, 2020

news image

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Read More

IMPROVED PHARMA CONTINUES TO EXPAND THEIR OFFERINGS TO MEET CUSTOMER NEEDS

Improved Pharma | September 15, 2020

news image

Improved Pharma has expanded their offerings by acquiring S. I. Photonics’ top-of-the-line spectrophotometer, model 440. This model has a high sensitivity, low noise CCD detector that enables the collection of a full spectrum within a second. The power of this instrument is enhanced by the number of accessories and dip probes that permit easy sampling of a variety of materials. The dip probes can be used to monitor reactions in real-time and are especially useful for obtaining quick data d...

Read More

Pharmacy Market

ALNYLAM ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR OXLUMO® (LUMASIRAN) IN ADVANCED PRIMARY HYPEROXALURIA TYPE 1

Alnylam Pharmaceuticals, Inc. | October 07, 2022

news image

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration approved a label expansion for OXLUMO® an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients. The approval is based on positive efficacy and safety results of the ILLUMINATE-C Phase 3 study of OXLUMO in patients wi...

Read More

Pharmacy Market

KAIROS PHARMA RECEIVED FDA APPROVAL OF THE IND APPLICATION FOR AN INVESTIGATIONAL NEW DRUG

Kairos Pharma, Ltd. | March 15, 2022

news image

Kairos Pharma, Ltd. a privately-held clinical-stage biotechnology company focused on cancer drug resistance and immunotherapy, announced today that its activated T cell therapy, KROS 201, has received FDA approval to move forward with a Phase 1 clinical trial in patients with recurrent glioblastoma. Kairos Pharma is funding the phase I trial, which will occur at Cedars Sinai Medical Center in Los Angeles. John Yu, M.D., Kairos CEO, commented, "This IND acceptance is the secon...

Read More
news image

CANNABIS INDUSTRY GIANT WAYOFLEAF.COM EXPANDS HEALTH-SPECIFIC CONTENT, INTRODUCES MEDICAL REVIEW TEAM

Prnewswire | September 30, 2020

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Read More
news image

IMPROVED PHARMA CONTINUES TO EXPAND THEIR OFFERINGS TO MEET CUSTOMER NEEDS

Improved Pharma | September 15, 2020

Improved Pharma has expanded their offerings by acquiring S. I. Photonics’ top-of-the-line spectrophotometer, model 440. This model has a high sensitivity, low noise CCD detector that enables the collection of a full spectrum within a second. The power of this instrument is enhanced by the number of accessories and dip probes that permit easy sampling of a variety of materials. The dip probes can be used to monitor reactions in real-time and are especially useful for obtaining quick data d...

Read More
news image

Pharmacy Market

ALNYLAM ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR OXLUMO® (LUMASIRAN) IN ADVANCED PRIMARY HYPEROXALURIA TYPE 1

Alnylam Pharmaceuticals, Inc. | October 07, 2022

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration approved a label expansion for OXLUMO® an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients. The approval is based on positive efficacy and safety results of the ILLUMINATE-C Phase 3 study of OXLUMO in patients wi...

Read More
news image

Pharmacy Market

KAIROS PHARMA RECEIVED FDA APPROVAL OF THE IND APPLICATION FOR AN INVESTIGATIONAL NEW DRUG

Kairos Pharma, Ltd. | March 15, 2022

Kairos Pharma, Ltd. a privately-held clinical-stage biotechnology company focused on cancer drug resistance and immunotherapy, announced today that its activated T cell therapy, KROS 201, has received FDA approval to move forward with a Phase 1 clinical trial in patients with recurrent glioblastoma. Kairos Pharma is funding the phase I trial, which will occur at Cedars Sinai Medical Center in Los Angeles. John Yu, M.D., Kairos CEO, commented, "This IND acceptance is the secon...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us